| Deal value | $1.7B |
|---|---|
| Share of market cap | 7.2% |
| Share of annual revenue | 11.8% |
Key highlights
- Viatris acquired all outstanding shares of Pacira BioSciences for $36.50 per share in cash
- Total transaction value is approximately $1.69 billion excluding related fees and expenses
- Tender offer resulted in 66.46% of outstanding shares being validly tendered by the expiration date
- Acquisition expected to generate between $90 million and $100 million in revenue for the remainder of 2026
- Pacira BioSciences has been delisted from the Nasdaq Global Select Market following the merger
What Is the Deal?
Viatris Inc. has successfully concluded its acquisition of Pacira BioSciences, Inc., a specialist in non-opioid pain management solutions. The transaction, valued at approximately $1.69 billion in total cash consideration, was completed on November 17, 2026, following a successful tender offer and subsequent merger. This acquisition, which was originally announced on October 8, 2026, results in Pacira becoming a wholly owned subsidiary of Viatris. Consequently, Pacira common stock has been delisted from the Nasdaq Global Select Market, marking a significant expansion of Viatris innovative medicines segment in the United States and diversifying its therapeutic offerings beyond traditional generics.
Deal Structure & Terms
- Viatris executed a tender offer to purchase all outstanding shares for $36.50 per share in cash
- The offer expired on November 16, 2026, with approximately 32.9 million shares validly tendered
- The merger was completed without a stockholder vote in accordance with Section 251(h) of Delaware law
- Total consideration of $1.69 billion was funded through cash on hand and available liquidity
- Non-tendered shares were converted into the right to receive the same cash price per share
Strategic Rationale
“Today marks an important milestone in the execution of our strategy to strengthen our U.S. innovative medicines business. With Pacira now part of Viatris, we are bringing together complementary portfolios, capabilities and expertise to establish a leadership position in non-opioid pain management. We are excited to welcome our new Pacira colleagues as we create new opportunities to make a meaningful difference for patients and accelerate our path to sustained revenue and earnings growth.”
Financial Context
Viatris anticipates that the integration of Pacira will contribute between $90 million and $100 million in total revenue for the remainder of the 2026 fiscal year. This forecast covers the operations of the acquired assets from the closing date of November 17 through December 31. The acquisition fits within Viatris broader financial profile, which includes an annual revenue base of approximately $14.3 billion and a current market capitalization of $23.6 billion. By utilizing $1.69 billion in cash for this transaction, Viatris is deploying capital toward high-margin innovative medicines to offset price erosion often seen in its legacy generic pharmaceutical segments.
Up 13.6% over the last month ($18.26 on 19 Oct → $20.74 on 16 Nov). Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $18.26 |
|---|---|
| 20 Oct | $18.65 |
| 21 Oct | $18.45 |
| 22 Oct | $18.48 |
| 23 Oct | $18.00 |
| 26 Oct | $18.29 |
| 27 Oct | $18.72 |
| 28 Oct | $18.77 |
| 29 Oct | $19.20 |
| 30 Oct | $19.04 |
| 2 Nov | $18.67 |
| 3 Nov | $18.92 |
| 4 Nov | $19.22 |
| 5 Nov | $18.97 |
| 6 Nov | $19.91 |
| 9 Nov | $20.49 |
| 10 Nov | $20.85 |
| 11 Nov | $21.06 |
| 12 Nov | $20.67 |
| 13 Nov | $20.82 |
| 16 Nov | $20.74 |
Management commentary
“Today marks an important milestone in the execution of our strategy to strengthen our U.S. innovative medicines business. With Pacira now part of Viatris, we are bringing together complementary portfolios, capabilities and expertise to establish a leadership position in non-opioid pain management. We are excited to welcome our new Pacira colleagues as we create new opportunities to make a meaningful difference for patients and accelerate our path to sustained revenue and earnings growth.”
| Share price | $20.59 |
|---|---|
| Market cap | $23.6B |
| Revenue (annual) | $14.3B |
| 1-month price change | +10.32% |
| Sector | HealthcareDrug Manufacturers - Specialty & Generic |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Viatris Inc. announcing the completion of the acquisition of Pacira BioSciences, Inc.
Track Viatris Inc live
Get the next Viatris Inc SEC filing seconds after it lands.




